212 related articles for article (PubMed ID: 28479535)
1. [Measurement of Prothrombin Fragment 1+2 for the Assessment of Anticoagulant Activity in Patients Treated with Warfarin or Non-vitamin K Antagonist Oral Anticoagulant].
Tomoda M; Yasaka M; Nakanishi Y; Takaguchi G; Nakamura A; Gotoh S; Kuwashiro T; Okada Y
Brain Nerve; 2017 May; 69(5):571-576. PubMed ID: 28479535
[TBL] [Abstract][Full Text] [Related]
2. Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.
Hagii J; Tomita H; Metoki N; Tamai Y; Saito S; Shiroto H; Hitomi H; Kamada T; Seino S; Takahashi K; Sasaki S; Yasujima M; Okumura K
Thromb Res; 2016 Dec; 148():9-14. PubMed ID: 27764730
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
4. Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment.
Tomita H; Hagii J; Metoki N; Saito S; Shiroto H; Hitomi H; Kamada T; Seino S; Takahashi K; Sasaki S; Yasujima M; Okumura K
J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1430-7. PubMed ID: 25843224
[TBL] [Abstract][Full Text] [Related]
5. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation.
Hitaka Y; Ogawa M; Zhang B; Goto S; Nagata Y; Morii J; Imaizumi S; Yasuda T; Matsumoto N; Matsunaga A; Saku K
J Cardiol; 2016 Dec; 68(6):529-535. PubMed ID: 26987789
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
7. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
Simons LA; Ortiz M; Freedman SB; Waterhouse BJ; Colquhoun D; Thomas G
Curr Med Res Opin; 2016 Nov; 32(11):1857-1861. PubMed ID: 27463735
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
9. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation.
Tamura A; Yamamoto E; Kawano Y
Am J Cardiol; 2020 Dec; 136():71-75. PubMed ID: 32946856
[TBL] [Abstract][Full Text] [Related]
11. Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
Xian Y; Hernandez AF; Harding T; Fonarow GC; Bhatt DL; Suter RE; Khan Y; Schwamm LH; Peterson ED
Am Heart J; 2016 Dec; 182():28-35. PubMed ID: 27914497
[TBL] [Abstract][Full Text] [Related]
12. Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy.
Takahashi H; Jimbo Y; Takano H; Abe H; Sato M; Fujii Y; Aizawa Y
Am J Cardiol; 2016 Jul; 118(2):222-5. PubMed ID: 27289294
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
14. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis System
Idemoto Y; Miura SI; Norimatsu K; Suematsu Y; Hitaka Y; Shiga Y; Morii J; Imaizumi S; Kuwano T; Iwata A; Zhang B; Ogawa M; Saku K
Heart Vessels; 2017 Mar; 32(3):309-316. PubMed ID: 27325226
[TBL] [Abstract][Full Text] [Related]
16. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
[TBL] [Abstract][Full Text] [Related]
17. [Anticoagulants after acute ischemic stroke with atrial fibrillation].
Terent A; Åsberg S; Oldgren J; Hijazi Z; Norrving B
Lakartidningen; 2016 Mar; 113():. PubMed ID: 26928683
[TBL] [Abstract][Full Text] [Related]
18. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Coleman CM; Khalaf S; Mould S; Wazni O; Kanj M; Saliba W; Cantillon D
Pacing Clin Electrophysiol; 2015 Jun; 38(6):731-7. PubMed ID: 25721150
[TBL] [Abstract][Full Text] [Related]
19. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
